Filter:
FOR IMMEDIATE RELEASE The Alpha-1 Foundation announces the selection of Mr. Scott Santarella as the new President and Chief Executive […]
Read More… from The Alpha-1 Foundation selects new President and Chief Executive Officer
Through the eyes of Joe Reidy, Alpha and Participant for 25 years: First Autumn Escape to the Cape Bike Trek […]
September 22, 2021- Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 […]
“We are pleased to hear that the Pfizer-BioNTech COVID-19 Vaccine has received full FDA approval. We strongly recommend that everyone receive […]
A company that profits from the sale of tobacco products that cause COPD should not profit from the sale of […]
Read More… from COPD Foundation Condemns Big Tobacco Acquisition of Pharmaceutical Company
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and […]
The HealthCare.gov Special Enrollment Period is coming to an end on August 15, 2021. The Centers for Medicare and Medicaid Services (CMS) […]
Read More… from HealthCare.gov Special Enrollment Period Enrollment Ends August 15!
Glen A. Perkins, 80, of Wildwood, FL passed away peacefully on July 24 at home. Glen will be remembered fondly […]
June 30, 2021 The Honorable Alejandro Mayorkas Secretary U.S. Department of Homeland Security RE: Concerns regarding donation of source plasma […]
Read More… from Alpha-1 Foundation Signs on to APLUS Plasma Collection Concerns Letter
FOR IMMEDIATE RELEASE: The Alpha-1 Foundation has established priorities that are important to its mission of proceeding as rapidly as […]
NPR ARTICLE: June 15, 2021 A small new study offers a glimmer of hope that giving organ transplant recipients a […]
Read More… from A 3rd Dose Of COVID Vaccines May Boost Immunity For Transplant Recipients
The Alpha-1 Foundation is proud to announce and introduce its newest Board of Director, Faron Schonfeld. Faron spent 18 years […]
Read More… from Alpha-1 Foundation welcomes new Board of Director, Faron Schonfeld
Thank you for being part of the 2021 Virtual Alpha-1 National Conference! You, the Alphas, are the center of everything […]
Read More… from Day 3 Recap: Virtual Alpha-1 National Conference
Thank you for participating in DAY TWO of the 2021 Virtual Alpha-1 National Conference. Today was a great day of interaction, […]
Read More… from DAY TWO RECAP: 2021 Virtual Alpha-1 National Conference
Thank you for registering and joining the first day of the 2021 Virtual Alpha-1 National Conference. Today we were joined […]
Read More… from DAY ONE RECAP: 2021 Virtual Alpha-1 National Conference
June 11, 2021 “The Alpha-1 Foundation looks forward to continuing to work with Vertex in their drive to develop primary […]
June 9, 2021- FOR IMMEDIATE RELEASE The 2021 Virtual Alpha-1 National Conference will take place from June 10th– June 12th, […]
Read More… from The Alpha-1 Foundation Launches the 2021 Virtual Alpha-1 National Conference
Jeanine D’Armiento, MD, PhD, Chair of the Alpha-1 Foundation Board of Directors, has been nominated and selected by the Columbia […]
Read More… from Dr. Jeanine D’Armiento receives distinguished honor at Columbia University
STATEMENT UPDATED: May 26, 2021 Please note, this statement is specific to the United States. If you are an individual […]
Read More… from Updated COVID-19 Guidance & Recommendations for Alphas
TO: Alpha-1 Community FROM: Alpha-1 Foundation Board of Directors RE: Leadership Transition Announcement DATE: 5/21/2021 We are writing to announce […]
Read More… from Alpha-1 Foundation Leadership Transition Announcement
1020 First Avenue • King of Prussia, PA 19406-0901 CSL.com CSLBehring.com May 21, 2021 ANNOUNCEMENT RECEIVED FROM CSL BEHRING CSL […]
Read More… from Announcement: ZEMAIRA Alpha-1 Proteinase Inhibitor (Human) Update
(MIAMI, FL) – The Alpha-1 Foundation is excited to announce our guest speaker, Sally Struthers, for the “All in for […]
May 6, 2021, WASHINGTON, D.C. – 32 organizations representing millions of people with pre-existing conditions urge Congress and the Administration […]
“The Arrowhead Pharmaceuticals Inc. interim study results from the open label phase 2 clinical ARO-AAT, a RNAi therapy, provide proof […]
